Abstract: A master-side control mechanism and a surgical robot are provided. The master-side control mechanism includes a base, two fixing frames, a rotating shaft rotatably connected to the two fixing frames and provided with a baffle, a first sensing device configured to sense the rotational movement of the rotating shaft, two handles located on both sides of the baffle and sleeved on the rotating shaft and capable of moving opposite to each other along the axial direction thereof, two second sensing devices configured to sense axial movements of the two handles corresponding to an advancing action and a retracting action and a control device. The control device is configured to control the slave-side execution apparatus to perform a twirling action based on the rotational movement of the rotating shaft and to perform the advancing or retracting action based on the axial movement of the handles.

Abstract: Disclosed are MGS peptides, MTS peptides, linkers and combinations combining any combination thereof. Disclosed are MGS peptides comprising the amino acid sequence of any of the sequences set forth in SEQ ID NOs: 1-8 Disclosed are MTS peptides comprising the amino acid sequence of any of the sequences set forth in SEQ ID NOS: 9-14. Disclosed are compositions comprising at least one MGS peptide conjugated to at least one MTS peptide, wherein the MGS peptide comprises the amino acid sequence of GFHNVYPYTWGGFSDIDLMADEI (SEQ ID NO: 1); EQRWVQMLHILQTRYAGEWPG (SEQ ID NO: 2); FQHINPFPYTYSMEDTDVEIK (SEQ ID NO: 3); or YAAWPASGAWT (SEQ ID NO: 4). In some aspects, the disclosed compositions can further comprise one or more linkers.

Abstract: Provided is a method for replicating a mirror nucleic acid, comprising: reacting a mirror nucleic acid template, a mirror nucleic acid primer and mirror dNTPs/rNTPs in the presence of a mirror nucleic acid polymerase, so as to obtain the mirror nucleic acid.

Abstract: Provided is a method for replicating a mirror nucleic acid, comprising: reacting a mirror nucleic acid template, a mirror nucleic acid primer and mirror dNTPs/rNTPs in the presence of a mirror nucleic acid polymerase, so as to obtain the mirror nucleic acid.

Abstract: The invention provides a pharmaceutical composition for injection comprising a NL-101 type compound and a preparation method thereof. The composition uses the NL-101 type compound as an active pharmaceutical ingredient, and the stability of the NL-101 type compound is improved by adding a chloride-containing stabilizing agent or using a co-solvent containing hydrochloric acid, so that the formulation can be stably produced and meet the requirements for clinical safe use.

Abstract: Disclosed are an azaphenalene-3-one derivative, its preparation method and its application, in the field of pharmaceutical synthesis. The derivative has the following Formula (I), wherein R is H, 2-fluoroethylamino, 2,2,2-trifluoroethylamino, diethylamino, pyrrolidinyl, imidazolyl, piperidinyl, morphinolinyl, 4-methylaminopiperidinyl, 4-dimethylaminopiperidinyl, (1-methylpiperidin-4-yl)methylamino, (1-phenylpiperidin-4-yl)methylamino, (1-benzylpiperidin-4-yl)methylamino, or 7-fluoro-3,4-dihydroisoquinoline-2(1H)-yl. The preparation method of the azaphenalene-3-one derivative is simple, the yield is high, post-treatment is easy, and purity is high. The derivative has high inhibitory activity against PARP enzyme. It establishes a foundation for researching better anti-tumor drugs using PARP inhibitors.

Abstract: Disclosed are an azaphenalene-3-one derivative, its preparation method and its application, in the field of pharmaceutical synthesis. The derivative has the following Formula (I), wherein R is H, 2-fluoroethylamino, 2,2,2-trifluoroethylamino, diethylamino, pyrrolidinyl, imidazolyl, piperidinyl, morphinolinyl, 4-methylaminopiperidinyl, 4-dimethylaminopiperidinyl, (1-methylpiperidin-4-yl)methylamino, (1-phenylpiperidin-4-yl)methylamino, (1-benzylpiperidin-4-yl)methylamino, or 7-fluoro-3,4-dihydroisoquinoline-2(1H)-yl. The preparation method of the azaphenalene-3-one derivative is simple, the yield is high, post-treatment is easy, and purity is high. The derivative has high inhibitory activity against PARP enzyme. It establishes a foundation for researching better anti-tumor drugs using PARP inhibitors.

Abstract: Provided is a method for replicating a mirror nucleic acid, comprising: reacting a mirror nucleic acid template, a mirror nucleic acid primer and mirror dNTPs/rNTPs in the presence of a mirror nucleic acid polymerase, so as to obtain the mirror nucleic acid.

Abstract: The invention provides a pharmaceutical composition for injection comprising a NL-101 type compound and a preparation method thereof. The composition uses the NL-101 type compound as an active pharmaceutical ingredient, and the stability of the NL-101 type compound is improved by adding a chloride-containing stabilizing agent or using a co-solvent containing hydrochloric acid, so that the formulation can be stably produced and meet the requirements for clinical safe use.

Abstract: Disclosed are an aza-phenalene-3-ketone derivative, a preparation method thereof and its application as a PARP inhibitor. The aza-phenalene-3-ketone derivative has the following structure: wherein R is hydrogen, methyl, ethyl, isopropyl, benzyl or 3-methyl-3-butenyl. The aza-phenalene-3-ketone derivative has very high activity for inhibiting PARP, thereby providing a good basis for new drug research of developing a nitrogen-doped phenalene-3-ketone compound as PARP inhibitor to treat cancer.

Abstract: Disclosed are an aza-phenalene-3-ketone derivative, a preparation method thereof and its application as a PARP inhibitor. The aza-phenalene-3-ketone derivative has the following structure: wherein R is hydrogen, methyl, ethyl, isopropyl, benzyl or 3-methyl-3-butenyl. The aza-phenalene-3-ketone derivative has very high activity for inhibiting PARP, thereby providing a good basis for new drug research of developing a nitrogen-doped phenalene-3-ketone compound as PARP inhibitor to treat cancer.

Abstract: The invention provides novel bis-pyridylpyridones which are antagonists at the melanin-concentrating hormone receptor 1 (MCHR1), pharmaceutical compositions containing them, processes for their preparation, and their use in therapy and for the treatment of obesity and diabetes.

Abstract: Polarized unsaturated functional groups is directly reduced by using metal amidoborane or derivatives thereof through double hydrogen transfer process. Over 99% conversion of reagents and high isolated yield of products can be achieved after reaction.